Objective: To examine whether mRNA circulating in maternal blood coding genes 36 regulating fetal growth are differentially expressed in 1) severe preterm FGR and 2) 37 at 28 weeks' gestation in pregnancies destined to develop FGR at term.
factors that also modulate their effects via the IGF system. There is mounting 91 evidence that abnormalities in the IGF system play a crucial role in the pathogenesis 92 of FGR. However, the literature has been conflicting as to whether FGR is associated 93 with changes in circulating IGF proteins in maternal blood.
94
Therefore in this study, we investigated whether mRNA of IGF1, IGF2, IGFBP-2,
95
IGF1R, PGH and ADAM12 were dysregulated in the maternal blood in pregnancies 96 affected by severe preterm FGR, and whether the circulating mRNA might reflect 97 placental gene expression. We also studied a second cohort where we prospectively 98 collected serial maternal samples from 28 weeks' gestation in a low risk population 99 and followed fetal growth until delivery. We identified cases with well-grown fetuses 100 at recruitment (as determined by ultrasound) but who exhibited a decline in growth 101 trajectory, developing FGR at term. We measured mRNA coding these six growth 102 factors in maternal blood from this cohort at 28 and 36 weeks' gestation to determine 103 their potential to predict term FGR.
M A N U S C R I P T
A C C E P T E D 
134
After birth the subjects were stratified into 3 cohorts ( 
155
Placental biopsies were obtained immediately after delivery by caesarean section.
156
Placental biopsies were taken from the maternal side of the placenta, to a depth of 157 2/3 of the placenta, avoiding the decidua. The biopsies were clear of obvious 158 infarction or calcification. Placental biopsies were washed in sterile PBS to remove 159 contamination by maternal blood, snap frozen and stored at -80C until processing.
160
RNA was extracted from peripheral whole maternal blood using the PAXgene Blood 
185
Significance was defined as p<0.05.
187
mRNA coding growth genes are differentially expressed in placenta from cases of 188 severe preterm FGR.
189
We first examined the expression of IGF1, IGF2, IGF1R, IGFBP2, PGH and ADAM12 190 in the placenta in severe preterm FGR (n=20), and compared them with preterm 191 (n=8) and term (n=8) controls. The clinical characteristics are described in Table 1 .
192
In preterm FGR there was a substantial increase in placental mRNA expression of 193 the following compared to preterm controls ( Fig. 1A 
201
To investigate whether circulating mRNA in the maternal circulation might reflect 202 changes in the placental transcriptome, the expression of these six genes were 203 measured in maternal blood (Fig. 1B) . The expression of all six genes in maternal 204 blood with severe preterm FGR closely correlated with the trends in the placental 205 transcriptome (compared with Fig. 1A) . Interestingly, the degree of fold change was 206 generally higher in maternal blood compared to placenta. Thus, in preterm FGR there 
224
the fold changes in the maternal blood were far greater than that seen in placenta.
225
There was a 2-fold increase in IGF1 in the placenta compared to a 4.8 fold increase 226 in the maternal blood with AREDF. However, there was no difference in expression 227 of IGFBP2, IGF1R or ADAM2 in either the placenta or maternal blood in FGR, 228 stratified according to the severity of umbilical artery Doppler resistance.
229
mRNA coding growth genes in maternal blood gestation are differentially expressed 230 at 28 and 36 weeks' in pregnancies destined to develop term FGR.
231
We next investigated whether mRNA coding growth genes in the maternal circulation 232 at mid-pregnancy can identify fetuses that are appropriately grown at 28 weeks We recruited 52 healthy pregnant women at 28 weeks, performing an ultrasound to 236 confirm apparent normal fetal growth (EFW >20 th centile) at the time of recruitment.
237
We then followed participants longitudinally, collecting maternal blood at 28 and 36 238 weeks gestation and tracking growth trajectory by performing another ultrasound at 239 36 weeks, then noting final birthweight ( Fig. 3 depicts how participants were 240 recruited).
241
Of the 52 participants, we identified 15 appropriate grown controls (AGA) where the 242 fetus clearly maintained growth trajectory ( Fig. 3B is an example of a clinical growth 243 chart plot where fetal growth was maintained) and 10 cases where growth trajectory 244 serially declined and the pregnancy ended up with FGR at term (birthweight <10 th 245 centile; Fig. 3C ). Clinical characteristics of this second cohort are shown in Table 2 .
246
None of the individuals in the second cohort developed pre-eclampsia. We then 247 compared the mRNA coding growth transcripts in the maternal blood among the AGA 248 controls and term FGR cases (Fig. 4 ).
249
Firstly we examined the expression of the growth transcripts across gestation in the 250 AGA controls. There was a non-significant increase in the expression of IGF1, IGF2 251 and PGH between 28 and 36 weeks, but no change across gestation in IGFBP2,
252
IGF1R and ADAM12.
253
We next examined whether the expression of the growth transcripts in maternal 254 blood was different between AGA and term FGR. There was a 2.2 fold increase in 255 IGF1 and IGFBP2 (p<0.05), a 2.7 fold increase in IGF2 (p<0.01) and a 3.0 fold 256 increase in PGH (p<0.01), in pregnancies on the way to developing FGR at term, but 257 with an estimated fetal weight still above the 10 th centile on ultrasound at 36 weeks 258 ( Fig. 4A ). If these women had only had an ultrasound assessment of fetal size at 36 259 weeks, it is unlikely term FGR would have been predicted. In contrast, in cases with 260 evolving term FGR, there was already evidence of differential expression of mRNA M A N U S C R I P T 
A C C E P T E D

264
Finally, we examined the expression of the growth transcripts in maternal blood at 28 265 weeks gestation. We confirmed on ultrasound that all fetuses were well grown at the 266 time of blood sampling and there were no risk factors for FGR. In contrast, the 267 expression of IGF2 (3.9 fold, p<0.01), PGH (2.7 fold, p<0.05) and IGFBP2 (2.1 fold, 268 p<0.05) were already significantly increased in pregnancies that would subsequently 269 develop FGR at term ( Figure 4B ). Thus these transcripts were altered more than 10 
281
Furthermore, there are no good cost effective biomarkers for FGR that can be 282 applied to a low risk population to either predict FGR or identify FGR already present 283 in utero.
284
We have investigated levels of mRNA circulating in maternal blood that code major 285 growth genes in pregnancy using two approaches: detection of severe preterm FGR 286 already present in-utero, and early prediction of FGR at term. In the severe preterm
287
FGR study, we found mRNA expression of six growth factors in the maternal blood 288 were dysregulated with severe preterm FGR, and mirrored trends seen in the 289 placental transcriptome. In addition, they were further dysregulated with increasing 290 severity of disease as determined by umbilical artery Doppler velocimetry. In our 291 second study, we recruited low risk women at 28 weeks and tracked fetal growth 292 longitudinally, and found mRNA coding growth genes in maternal circulation were 293 dysregulated as early as 28 weeks gestation in those women who subsequently 294 developed FGR. Therefore circulating growth factor RNA in the maternal blood may 295 be a promising method to both detect established preterm FGR and predict FGR at Interestingly, the trends in mRNA expression of all six growth genes in maternal 298 blood not only mirrored those seen in placenta but the fold changes were generally 299 much greater in maternal blood. We hypothesize the reason is that the origin of most 300 of the circulating mRNA is shed particles from the syncytiotrophoblast layer, the 301 same tissue layer that expresses the growth transcripts 18 . As such, mRNA in 302 maternal blood might be naturally enriched with IGF mRNA transcripts from the 303 syncytiotrophoblast. If correct, this lends support to the promise of exploiting free 304 circulating RNA of placental origin as a clinical biomarker.
305
Importantly, a strength of our study is the inclusion of both severe preterm FGR 306 cases and term FGR, diseases that are managed very differently in the clinic.
307
Preterm FGR occurs less frequently but has a strong association with perinatal 308 mortality and neonatal morbidity due to prematurity. Therefore identifying these 309 pregnancies to optimize timing of delivery is clinically important 5 . Term FGR is a 310 substantial contributor to perinatal mortality and notably, the incidence of stillbirth due 311 to FGR is at its peak after 38 weeks. Therefore, induction of labour in these 312 pregnancies is likely to yield the greatest clinical benefit with minimal harm.
313
Routine ultrasound applied to low risk pregnancies has not been shown to improve 314 perinatal outcome 19 
